Table 3 Difference in rate of variceal rebleed between MDT and non-MDT groups
From: The role of a multidisciplinary team in the management of portal hypertension
| Â | Before PSM | After PSM | ||
|---|---|---|---|---|
MDT | non-MDT | MDT | non-MDT | |
1-month actuarial survival | 0.976 (0.943–1) | 0.907 (0.881–0.935) | 0.982 (0.949–1) | 0.955 (0.917–0.994) |
2-month actuarial survival | 0.976 (0.943–1) | 0.885 (0.855–0.915) | 0.965 (0.918–1) | 0.91 (0.858–0.965) |
3-month actuarial survival | 0.976 (0.943–1) | 0.825 (0.79–0.861) | 0.965 (0.918–1) | 0.874 (0.814–0.938) |
6-month actuarial survival | 0.923 (0.858–0.992) | 0.765 (0.726–0.806) | 0.965 (0.918–1) | 0.818 (0.749–0.894) |
1-year actuarial survival | 0.976 (0.943–1) | 0.907 (0.881–0.935) | 0.939 (0.873–1) | 0.75 (0.672–0.836) |